CF
CRNX icon

Cantor Fitzgerald’s Crinetics Pharmaceuticals CRNX Stock Holding History

Cantor Fitzgerald’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-32,562
Closed -$587K – 575
2023
Q2 		$587K Buy
+32,562
New +$649K 0.01% 349

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Cantor Fitzgerald's CRNX Position: Q3 2023 in Review

Cantor Fitzgerald sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2023, closing a stake of 32,562 shares — an estimated $587K sold.

Cantor Fitzgerald first reported a position in CRNX in Q2 2023 and held it in 1 quarter. The position peaked at $587K in Q2 2023. 171 funds tracked by Wall St. Rank hold CRNX as of Q3 2023.

  • Cantor Fitzgerald reported no remaining Crinetics Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Cantor Fitzgerald sold 32,562 Crinetics Pharmaceuticals shares in Q3 2023, an estimated $587K.
  • Cantor Fitzgerald first reported a position in Crinetics Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Cantor Fitzgerald's Crinetics Pharmaceuticals position peaked at $587K in Q2 2023.
  • 171 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2023.

Based on Cantor Fitzgerald's 13F filing for Q3 2023, filed 14 Nov 2023.